Terns Pharmaceuticals, Inc. (NASDAQ:TERN) is among the 20 Best Performing Stocks in 2025. On December 11, 2025, TheFly reported that Citizens boosted its price goal for Terns Pharmaceuticals, Inc.

We recently published 10 Market Stars Behind Millionaire-Making in 2025. Terns Pharmaceuticals, Inc. (NASDAQ:TERN) is one of the top performers. Terns Pharmaceuticals climbed by 629.64 percent in 2025 ...

After launching its first-ever battery-electric Class 8 truck at the 2024 ACT Expo, the Toyota Hino-backed Tern brand announced the launch of its second electric semi truck. Meet the new Tern RC8 6×2 ...

KYIV, Dec 15 (Reuters) - Ukrainian long-range drones struck a Russian oil production platform in the Caspian Sea for the third time in a week, a security source told Reuters on Monday. The latest ...

Adam Feuerstein is a senior writer and biotech columnist, reporting on the crossroads of drug development, business, Wall Street, and biotechnology. He is also a co-host of the weekly biotech podcast ...

The average one-year price target for Terns Pharmaceuticals (NasdaqGS:TERN) has been revised to $31.05 / share. This is an increase of 16.10% from the prior estimate of $26.75 dated November 14, 2025.

Tern, the technology platform designed for travel agents, is launching a new expansion of its platform with new booking technology through Project Expedition and future travel insurance partnerships.

Urban e-bike maker Tern just hit a major milestone in one of the toughest proving grounds on the planet: New York City. The company announced that its fleet partners have now logged more than one ...

Travel advisor tech platform Tern has added booking capability, enabling advisors to book Project Expedition's tours, activities and attractions. Tern intends to add travel insurance providers Arch ...

Tern fixes the biggest issue with its flagship folding ebike Taiwan's Tern Bicycles has listened to its customers and delivered a belt-drive Vektron folding ebike as part of the fourth-generation ...

Fintel reports that on November 13, 2025, Mizuho maintained coverage of Terns Pharmaceuticals (NasdaqGS:TERN) with a Outperform recommendation. Analyst Price Forecast Suggests 22.09% Downside As of ...

Terns Pharmaceuticals, Inc. ( (TERN)) has released its Q3 earnings. Here is a breakdown of the information Terns Pharmaceuticals, Inc. presented to its investors. Terns Pharmaceuticals, Inc. is a ...